Vertex Pharmaceuticals (VRTX) Non-Current Deffered Revenue (2009 - 2017)

Vertex Pharmaceuticals' Non-Current Deffered Revenue history runs 9 years deep, the most recent figure standing at $1.7 million for Q4 2017.

• In Q4 2017, Non-Current Deffered Revenue fell 73.97% year-over-year to $1.7 million; the TTM figure through Dec 2017 stood at $1.7 million (down 73.97% YoY), while the FY2017 annual figure was $1.7 million, down 73.97% from the prior year.
• Non-Current Deffered Revenue was $1.7 million for Q4 2017 at Vertex Pharmaceuticals, down from $2.9 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $90.3 million in Q1 2013 to a low of $1.7 million in Q4 2017.
• Historically, Non-Current Deffered Revenue has averaged $28.1 million across 5 years, with a median of $19.3 million in 2015.
• The sharpest annual moves came in 2013 and 2017: Non-Current Deffered Revenue slipped 22.28% in 2013, then slumped 73.97% in 2017.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $49.5 million in 2013, then sank by 43.78% to $27.8 million in 2014, then plunged by 65.07% to $9.7 million in 2015, then tumbled by 31.73% to $6.6 million in 2016, then slumped by 73.97% to $1.7 million in 2017.
• The last three Non-Current Deffered Revenue figures came in at $1.7 million (Q4 2017), $2.9 million (Q3 2017), and $4.2 million (Q2 2017), per Business Quant data.